eMedicine Specialties > Pediatrics: Cardiac Disease and Critical Care Medicine > Neonatology

Pulmonary Interstitial Emphysema

Author: Abhay J Bhatt, MD, MBBS, Assistant Professor, Department of Pediatrics, Division of Newborn Medicine, University of Mississippi Medical Center
Coauthor(s): Rita M Ryan, MD, Professor of Pediatrics, Chief, Division of Neonatology, Director, Neonatal-Perinatal Medicine Fellowship Program, University at Buffalo, State University of New York, Women's and Children's Hospital of Buffalo
Contributor Information and Disclosures

Updated: Apr 16, 2009

Introduction

Background

Pulmonary interstitial emphysema (PIE) is a collection of gases outside of the normal air passages and inside the connective tissue of the peribronchovascular sheaths, interlobular septa, and visceral pleura secondary to alveolar and terminal bronchiolar rupture. Pulmonary interstitial emphysema is more frequent in premature infants who require mechanical ventilation for severe lung disease. Once pulmonary interstitial emphysema is diagnosed, intensive respiratory management is required to reduce mortality and morbidity.

This radiograph, obtained from a premature infant...

This radiograph, obtained from a premature infant at 26 weeks' gestation, shows characteristic radiographic changes of pulmonary interstitial emphysema (PIE) of the right lung.

This radiograph, obtained from a premature infant...

This radiograph, obtained from a premature infant at 26 weeks' gestation, shows characteristic radiographic changes of pulmonary interstitial emphysema (PIE) of the right lung.


Pathophysiology

Pulmonary interstitial emphysema often occurs in conjunction with respiratory distress syndrome (RDS), but other predisposing etiologic factors include meconium aspiration syndrome (MAS), amniotic fluid aspiration, and infection.

Positive pressure ventilation (PPV) and reduced lung compliance are significant predisposing factors. However, in extremely premature infants, pulmonary interstitial emphysema can occur at low mean airway pressure and probably reflects increased sensitivity of the underdeveloped lung to stretch. Pulmonary interstitial emphysema has been rarely reported in the absence of mechanical ventilation or continuous positive airway pressure. The process of pulmonary interstitial emphysema is initiated when air ruptures from the alveolar airspace and small airways into the perivascular tissue of the lung.

Infants with RDS have an initial increase in interstitial and perivascular fluid that rapidly declines over the first few days of life. This fluid may obstruct the movement of gas from ruptured alveoli or airways to the mediastinum, causing an increase of PIE. Another possible mechanism for entrapment of air in the interstitium is the increased amount of pulmonary connective tissue in the immature lung. The entrapment of air in the interstitium may result in a vicious cycle that causes compression atelectasis of the adjacent lung, which then necessitates a further increase in ventilatory pressure with still more escape of air into the interstitial tissues.

Plenat et al described two topographic varieties of air leak: intrapulmonary pneumatosis and intrapleural pneumatosis.1 . In the intrapulmonary type, which is more common in premature infants, the air remains trapped inside the lung and frequently appears on the surface of the lung, bulging under the pleura in the area of interlobular septa. This phenomenon develops with high frequency on the costal surface and the anterior and inferior edges but can involve all of the pulmonary areas. In the intrapleural variety, which is more common in more mature infants with compliant lungs, the abnormal air pockets are confined to the visceral pleura, often affecting the mediastinal pleura. The air of pulmonary interstitial emphysema may be located inside the pulmonary lymphatic network.2

The extent of pulmonary interstitial emphysema can vary. It can present as an isolated interstitial bubble, several slits, lesions involving the entire portion of one lung, or diffuse involvement of both lungs. Pulmonary interstitial emphysema does not preferentially localize in any one of the 5 pulmonary lobes.

Pulmonary interstitial emphysema compresses adjacent functional lung tissue and vascular structures and hinders both ventilation and pulmonary blood flow, resulting in impedance of oxygenation, ventilation, and blood pressure. This further compromises the already critically ill infant with a significant increase in mortality and morbidity. Pulmonary interstitial emphysema can completely regress or decompress into adjacent spaces, causing pneumomediastinum, pneumothorax, pneumopericardium, pneumoperitoneum, or subcutaneous emphysema.3

Frequency

United States

The prevalence of pulmonary interstitial emphysema widely varies with the population studied. In a study by Gaylord et al, pulmonary interstitial emphysema developed in 3% of infants admitted to the neonatal ICU (NICU).4 In a retrospective case-controlled study, 24% (11 of 45) extremely low birth weight infants developed pulmonary interstitial emphysema.5 This study was done in the present era of tocolysis, antenatal steroids, and postnatal surfactant administration; however, all infants included in the study were treated with conventional ventilator in the assist-control mode before the onset of pulmonary interstitial emphysema.

Reported incidence of pulmonary interstitial emphysema in published clinical trials can be useful. In a randomized trial of surfactant replacement therapy at birth, in premature infants born at 25-29 weeks' gestation, Kendig et al reported pulmonary interstitial emphysema in 8 of 31 (26%) control neonates and in 5 of 34 (15%) surfactant-treated neonates.6 Another randomized controlled trial of prophylaxis versus treatment with bovine surfactant in neonates born at less than 30 weeks' gestation included 2 of 62 (3%) early surfactant-treated neonates, 5 of 60 (8%) late surfactant-treated neonates, and 15 of 60 (25%) control neonates with pulmonary interstitial emphysema7 . Kattwinkel et al compared prophylactic surfactant administration versus the early treatment of RDS with calf lung surfactant in neonates born at 29-32 weeks' gestation; 3 of 627 neonates in the prophylaxis group and 3 of 621 neonates in the early treatment group developed pulmonary interstitialemphysema.8 This information suggests a higher incidence of pulmonary interstitial emphysema in more immature infants as well as those with late surfactant therapy.

International

Studies reflecting international frequency demonstrated that 2-3% of all infants in NICUs develop pulmonary interstitial emphysema.9,10 When limiting the population studied to premature infants, this frequency increases to 20-30%, with the highest frequencies occurring in infants weighing fewer than 1000 g.11 In another study of low birth weight infants, the incidence of pulmonary interstitial emphysema was 42% in infants with birth weight of 500-799 g, 29% in those with birth weight of 800-899 g, and 20% in those with birth weight of 900-999 g.12 Minimal information is available about the prevalence of pulmonary interstitial emphysema in the postsurfactant era. In a prospective multicenter trial comparing early high-frequency oscillatory ventilation (HFOV) and conventional ventilation in preterm infants of fewer than 30 weeks' gestation with RDS, 15 of 139 (11%) infants in the high-frequency group and 15 of 134 (11%) infants in the conventional group developed pulmonary interstitialemphysema.9

Mortality/Morbidity

The mortality rate associated with pulmonary interstitial emphysema is reported to be as high as 53-67%.4,11 Lower mortality rates of 24% and 38% reported in other studies could result from differences in population selection.10,13 Morisot et al reported an 80% mortality rate with pulmonary interstitial emphysema in infants with birth weight of fewer than 1600 g and severe RDS.14 The early appearance of pulmonary interstitial emphysema (<48 h after birth) is associated with increased mortality, but this may reflect the severity of the underlying parenchymal disease.14,10

In survivors, morbidity is also high. Pulmonary interstitial emphysema can predispose an infant to other air leaks. In a study by Greenough et al, 31 of 41 infants with pulmonary interstitial emphysema developed pneumothorax, compared with 41 of 169 infants without pulmonary interstitial emphysema.13 In addition, 21 of 41 babies with pulmonary interstitial emphysema developed intraventricular hemorrhage (IVH), compared with 39 of 169 among infants without pulmonary interstitial emphysema. Pulmonary interstitial emphysema may not resolve for 2-3 weeks; therefore, it can increase the length of time of mechanical ventilation and the incidence of bronchopulmonary dysplasia. Some infants may develop chronic lobar emphysema, which may require surgical lobectomies.

In a more recent study in the postsurfactant era, 4 of 11 infants with pulmonary interstitial emphysema developed severe IVH (grade 2 or higher) compared with 4 of 34 infants without pulmonary interstitial emphysema. Additionally, pulmonary interstitial emphysema remained significantly associated with death (odds ratio, 14.4; 95% confidence interval [CI], 1-208; P = 0.05).5

Sex

In a study by Plenat et al, pulmonary interstitial emphysema developed equally in both sexes (21 males, 18 females). Although these data also included cases with intrapleural pneumatosis, no relationship between sex and type of interstitial pneumatosis is noted.1

Age

Pulmonary interstitial emphysema is more common in infants of lower gestational age. Pulmonary interstitial emphysema usually occurs within the first weeks of life. Development of pulmonary interstitial emphysema within the first 24-48 hours after birth is often associated with extreme prematurity, very low birth weight, perinatal asphyxia, and/or neonatal sepsis and frequently indicates a grave prognosis.

Clinical

History

Pulmonary interstitial emphysema (PIE) is a radiographic and pathologic diagnosis. In most cases, the discovery of pulmonary interstitial emphysema may be preceded by a decline in the baby's clinical condition. Hypotension and difficulty in oxygenation and ventilation can suggest the development of pulmonary interstitial emphysema. Alternatively, the baby can present with the signs of one of the complications of pulmonary interstitial emphysema, such as pneumothorax. Sometimes, pulmonary interstitial emphysema becomes apparent following reexpansion of a collapsed lung after drainage of a pneumothorax.

Physical

No specific signs of pulmonary interstitial emphysema are reported. Overinflation of the chest wall and crepitations on auscultation on the affected side may be present.

Causes

Risk factors include the following:

  • Prematurity
  • Respiratory distress syndrome (RDS)
  • Meconium aspiration syndrome (MAS)
  • Amniotic fluid aspiration
  • Infection - Neonatal sepsis, pneumonia, or both
  • Low Apgar score or need for positive pressure ventilation (PPV) during resuscitation at birth
  • Use of high peak airway pressures on mechanical ventilation
  • Incorrect positioning of the endotracheal tube in one bronchus

More on Pulmonary Interstitial Emphysema

Overview: Pulmonary Interstitial Emphysema
Differential Diagnoses & Workup: Pulmonary Interstitial Emphysema
Treatment & Medication: Pulmonary Interstitial Emphysema
Follow-up: Pulmonary Interstitial Emphysema
Multimedia: Pulmonary Interstitial Emphysema
References

References

  1. Plenat F, Vert P, Didier F, Andre M. Pulmonary interstitial emphysema. Clin Perinatol. Sep 1978;5(2):351-75. [Medline].

  2. Wood BP, Anderson VM, Mauk JE, Merritt TA. Pulmonary lymphatic air: locating "pulmonary interstitial emphysema" of the premature infant. AJR Am J Roentgenol. May 1982;138(5):809-14. [Medline].

  3. Cunningham K, Paes BA, Symington A. Pulmonary interstitial emphysema: a review. Neonatal Netw. Aug 1992;11(5):7-16, 29-31. [Medline].

  4. Gaylord MS, Thieme RE, Woodall DL, Quissell BJ. Predicting mortality in low-birth-weight infants with pulmonary interstitial emphysema. Pediatrics. Aug 1985;76(2):219-24. [Medline].

  5. Verma RP, Chandra S, Niwas R, Komaroff E. Risk factors and clinical outcomes of pulmonary interstitial emphysema in extremely low birth weight infants. J Perinatol. Mar 2006;26(3):197-200. [Medline].

  6. Kendig JW, Notter RH, Cox C, et al. Surfactant replacement therapy at birth: final analysis of a clinical trial and comparisons with similar trials. Pediatrics. Nov 1988;82(5):756-62. [Medline].

  7. Dunn MS, Shennan AT, Zayack D, Possmayer F. Bovine surfactant replacement therapy in neonates of less than 30 weeks' gestation: a randomized controlled trial of prophylaxis versus treatment. Pediatrics. Mar 1991;87(3):377-86. [Medline].

  8. Kattwinkel J, Bloom BT, Delmore P, et al. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Pediatrics. Jul 1993;92(1):90-8. [Medline].

  9. Moriette G, Paris-Llado J, Walti H, et al. Prospective randomized multicenter comparison of high-frequency oscillatory ventilation and conventional ventilation in preterm infants of less than 30 weeks with respiratory distress syndrome. Pediatrics. Feb 2001;107(2):363-72. [Medline][Full Text].

  10. Heneghan MA, Sosulski R, Alarcon MB. Early pulmonary interstitial emphysema in the newborn: a grave prognostic sign. Clin Pediatr (Phila). Jul 1987;26(7):361-5. [Medline].

  11. Hart SM, McNair M, Gamsu HR, Price JF. Pulmonary interstitial emphysema in very low birthweight infants. Arch Dis Child. Aug 1983;58(8):612-5. [Medline].

  12. Yu VY, Wong PY, Bajuk B, Szymonowicz W. Pulmonary interstitial emphysema in infants less than 1000 g at birth. Aust Paediatr J. Aug 1986;22(3):189-92. [Medline].

  13. Greenough A, Dixon AK, Roberton NR. Pulmonary interstitial emphysema. Arch Dis Child. Nov 1984;59(11):1046-51. [Medline].

  14. Morisot C, Kacet N, Bouchez MC, et al. Risk factors for fatal pulmonary interstitial emphysema in neonates. Eur J Pediatr. Apr 1990;149(7):493-5. [Medline].

  15. Campbell RE. Intrapulmonary interstitial emphysema: a complication of hyaline membrane disease. Am J Roentgenol Radium Ther Nucl Med. Nov 1970;110(3):449-56. [Medline].

  16. Schwartz AN, Graham CB. Neonatal tension pulmonary interstitial emphysema in bronchopulmonary dysplasia: treatment with lateral decubitus positioning. Radiology. Nov 1986;161(2):351-4. [Medline].

  17. Brooks JG, Bustamante SA, Koops BL, et al. Selective bronchial intubation for the treatment of severe localized pulmonary interstitial emphysema in newborn infants. J Pediatr. Oct 1977;91(4):648-52. [Medline].

  18. Chalak LF, Kaiser JR, Arrington RW. Resolution of pulmonary interstitial emphysema following selective left main stem intubation in a premature newborn: an old procedure revisited. Paediatr Anaesth. Feb 2007;17(2):183-6. [Medline].

  19. Weintraub Z, Oliven A, Weissman D, Sonis Z. A new method for selective left main bronchus intubation in premature infants. J Pediatr Surg. Jun 1990;25(6):604-6. [Medline].

  20. Keszler M, Donn SM, Bucciarelli RL, et al. Multicenter controlled trial comparing high-frequency jet ventilation and conventional mechanical ventilation in newborn infants with pulmonary interstitial emphysema. J Pediatr. Jul 1991;119(1 ( Pt 1)):85-93. [Medline].

  21. Clark RH, Gerstmann DR, Null DM, et al. Pulmonary interstitial emphysema treated by high-frequency oscillatory ventilation. Crit Care Med. Nov 1986;14(11):926-30. [Medline].

  22. Fitzgerald D, Willis D, Usher R, et al. Dexamethasone for pulmonary interstitial emphysema in preterm infants. Biol Neonate. 1998;73(1):34-9. [Medline].

  23. Leonidas JC, Hall RT, Rhodes PG. Conservative management of unilateral pulmonary interstitial emphysema under tension. J Pediatr. Nov 1975;87(5):776-8. [Medline].

  24. Dear PR, Conway SP. Treatment of severe bilateral interstitial emphysema in a baby by artificial pneumothorax and pneumonotomy [letter]. Lancet. Feb 4 1984;1(8371):273-5. [Medline].

  25. Dordelmann M, Schirg E, Poets CF, Ure B, Gluer S, Bohnhorst B. Therapeutic lung puncture for diffuse unilateral pulmonary interstitial emphysema in preterm infants. Eur J Pediatr Surg. Aug 2008;18(4):233-6. [Medline].

  26. Levine DH, Trump DS, Waterkotte G. Unilateral pulmonary interstitial emphysema: a surgical approach to treatment. Pediatrics. Oct 1981;68(4):510-4. [Medline].

  27. Ahluwalia JS, Rennie JM, Wells FC. Successful outcome of severe unilateral pulmonary interstitial emphysema after bi-lobectomy in a very low birthweight infant. J R Soc Med. Mar 1996;89(3):167P-8P. [Medline][Full Text].

  28. Gessler P, Toenz M, Gugger M, Pfenninger J. Lobar pulmonary interstitial emphysema in a premature infant on continuous positive airway pressure using nasal prongs. Eur J Pediatr. Apr 2001;160(4):263-4. [Medline].

  29. Martinez-Frontanilla LA, Hernandez J, Haase GM, Burrington JD. Surgery of acquired lobar emphysema in the neonate. J Pediatr Surg. Aug 1984;19(4):375-9. [Medline].

  30. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2001;CD000510. [Medline].

  31. Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev. Oct 17 2007;CD003063. [Medline].

  32. [Best Evidence] Soll R, Ozek E. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database Syst Rev. Jan 21 2009;CD000141. [Medline].

  33. Pohlandt F, Saule H, Schroder H, et al. Decreased incidence of extra-alveolar air leakage or death prior to air leakage in high versus low rate positive pressure ventilation: results of a randomised seven-centre trial in preterm infants. Eur J Pediatr. Dec 1992;151(12):904-9. [Medline].

  34. [Best Evidence] Henderson-Smart DJ, Cools F, Bhuta T, Offringa M. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. Cochrane Database Syst Rev. Jul 18 2007;CD000104. [Medline].

  35. Moriette G, Paris-Llado J, Walti H, et al. Prospective randomized multicenter comparison of high-frequency oscillatory ventilation and conventional ventilation in preterm infants of less than 30 weeks with respiratory distress syndrome. Pediatrics. Feb 2001;107(2):363-72. [Medline].

  36. Bhuta T, Henderson-Smart DJ. Rescue high frequency oscillatory ventilation versus conventional ventilation for pulmonary dysfunction in preterm infants. Cochrane Database Syst Rev. 2000;(2):CD000438. [Medline].

  37. Bhuta T, Henderson-Smart DJ. Elective high frequency jet ventilation versus conventional ventilation for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev. 2000;(2):CD000328. [Medline].

  38. [Best Evidence] McCallion N, Davis PG, Morley CJ. Volume-targeted versus pressure-limited ventilation in the neonate. Cochrane Database Syst Rev. 2005;CD003666. [Medline].

Further Reading

Keywords

pulmonary interstitial emphysema, PIE, respiratory distress syndrome, RDS, meconium aspiration syndrome, MAS, amniotic fluid aspiration, intrapulmonary pneumatosis, intrapleural pneumatosis, pneumomediastinum, pneumothorax, pneumopericardium, pneumoperitoneum, subcutaneous emphysema, bronchopulmonary dysplasia, chronic lobar emphysema, intraventricular hemorrhage, IVH, prematurity, very low birth weight, perinatal asphyxia, neonatal sepsis, pneumonia, positive pressure ventilation

Contributor Information and Disclosures

Author

Abhay J Bhatt, MD, MBBS, Assistant Professor, Department of Pediatrics, Division of Newborn Medicine, University of Mississippi Medical Center
Abhay J Bhatt, MD, MBBS is a member of the following medical societies: American Academy of Pediatrics
Disclosure: Nothing to disclose.

Coauthor(s)

Rita M Ryan, MD, Professor of Pediatrics, Chief, Division of Neonatology, Director, Neonatal-Perinatal Medicine Fellowship Program, University at Buffalo, State University of New York, Women's and Children's Hospital of Buffalo
Rita M Ryan, MD is a member of the following medical societies: American Academy of Pediatrics, American Thoracic Society, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Medical Editor

Steven M Donn, MD, Professor of Pediatrics, Director, Neonatal-Perinatal Medicine, Department of Pediatrics, University of Michigan Health System
Steven M Donn, MD is a member of the following medical societies: American Pediatric Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Brian S Carter, MD, FAAP, Professor of Pediatrics (Neonatology), Vanderbilt University School of Medicine; Co-director, Pediatric Advance Comfort Team, Monroe Carell Jr Children's Hospital at Vanderbilt
Brian S Carter, MD, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Hospice and Palliative Medicine, American Academy of Pediatrics, American Society for Bioethics and Humanities, American Society of Law Medicine and Ethics, National Hospice and Palliative Care Organization, and Southern Society for Pediatric Research
Disclosure: Nothing to disclose.

CME Editor

Carol L Wagner, MD, Professor of Pediatrics, Medical University of South Carolina
Carol L Wagner, MD is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American Medical Women's Association, American Public Health Association, American Society for Bone and Mineral Research, American Society for Clinical Nutrition, Massachusetts Medical Society, National Perinatal Association, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Chief Editor

Ted Rosenkrantz, MD, Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine
Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Pediatric Society, Connecticut State Medical Society, Eastern Society for Pediatric Research, and Society for Pediatric Research
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.